LifeStance Health Group annual cash and equivalents
2019
2021
2022
2023
2024
2025
LifeStance Health Group Cash & Equivalents Growth & History (LFST)
LifeStance Health Group's cash and equivalents was $248.6M for fiscal 2025.
View full LifeStance Health Group company overviewLifeStance Health Group annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $248.6M | $94.1M | +60.86% |
| 2024 | 2024-12-31 | $154.6M | $75.7M | +96.10% |
| 2023 | 2023-12-31 | $78.8M | −$29.8M | −27.43% |
| 2022 | 2022-12-31 | $108.6M | −$39.4M | −26.62% |
| 2021 | 2021-12-31 | $148.0M | — | — |
| 2019 | 2019-12-31 | $3.5M | — | — |
LifeStance Health Group quarterly cash and equivalents
As of Dec 31, 2020
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $225.9M | $37.0M | +19.59% |
| Q1 2026 | 2026-03-31 | $194.8M | $60.5M | +45.01% |
| Q4 2025 | 2025-12-31 | $248.6M | $94.1M | +60.86% |
| Q3 2025 | 2025-09-30 | $203.9M | $101.3M | +98.71% |
| Q2 2025 | 2025-06-30 | $188.9M | $102.0M | +117.24% |
| Q1 2025 | 2025-03-31 | $134.3M | $84.9M | +171.65% |
| Q4 2024 | 2024-12-31 | $154.6M | $75.7M | +96.10% |
| Q3 2024 | 2024-09-30 | $102.6M | $60.0M | +140.85% |
| Q2 2024 | 2024-06-30 | $87.0M | $7.4M | +9.25% |
| Q1 2024 | 2024-03-31 | $49.5M | −$18.8M | −27.59% |
| Q4 2023 | 2023-12-31 | $78.8M | −$29.8M | −27.43% |
| Q3 2023 | 2023-09-30 | $42.6M | −$47.7M | −52.84% |
| Q2 2023 | 2023-06-30 | $79.6M | −$17.1M | −17.67% |
| Q1 2023 | 2023-03-31 | $68.3M | −$45.7M | −40.09% |
| Q4 2022 | 2022-12-31 | $108.6M | −$39.4M | −26.62% |
| Q3 2022 | 2022-09-30 | $90.3M | −$121.8M | −57.41% |
| Q2 2022 | 2022-06-30 | $96.7M | −$179.5M | −64.99% |
| Q1 2022 | 2022-03-31 | $114.0M | — | — |
| Q4 2021 | 2021-12-31 | $148.0M | $129.2M | +686.18% |
| Q3 2021 | 2021-09-30 | $212.1M | — | — |
| Q2 2021 | 2021-06-30 | $276.2M | — | — |
| As of Dec 31, 2020 | 2020-12-31 | $18.8M | — | — |
LifeStance Health Group cash and equivalents trends
Between the periods ended 2019-12-31 and 2025-12-31, LifeStance Health Group's cash and equivalents increased from $3.5M to $248.6M, a change of $245.2M. The latest reported quarter, Q2 2026, shows $225.9M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LifeStance Health Group source filings ↗